Neel Agarwal, Julie St. John, Vikas Sunder, Ashish Sarraju, Luke J. Laffin
{"title":"Association of Systolic Blood Pressure Time in Target Range With Cardiovascular Events Among PRECISION Participants","authors":"Neel Agarwal, Julie St. John, Vikas Sunder, Ashish Sarraju, Luke J. Laffin","doi":"10.1111/jch.70009","DOIUrl":null,"url":null,"abstract":"<p>Blood pressure (BP) is a dynamic vital sign with variability. Novel metrics that account for BP variability and longitudinal control are gaining interest, such as time in target range (TTR) assessments. TTR is the percentage of time a patient's BP is within a desired range. We sought to determine if systolic BP TTR was associated with major adverse cardiovascular events (MACE) among participants in the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen) trial. PRECISION was a 24 081-participant cardiovascular (CV) outcomes trial comparing celecoxib, naproxen, or ibuprofen in participants with increased CV risk. Systolic BP was in the target range if it was between 110 and 130 mm Hg. TTR was determined via traditional and Rosendaal linear interpolation (RLI) methods. Participants were categorized based on TTR achieved, <25%, 25%–<50%, 50%–<75%, or ≥75%. Hazard ratios (HR) and Kaplan–Meier survival curves were generated. Twenty thousand four hundred and eighty-seven participants had at least four BP readings available for analysis and a median follow-up of 27.6 ± 5.4 months. The cohort had a mean baseline BP of 125.2 mm Hg and a mean systolic BP of 127.5 mm Hg when accounting for all follow-up visits. A lower risk of MACE was observed among individuals with ≥75% TTR compared with those <25% using the traditional (adjusted HR 0.70, 95% CI 0.52–0.95, <i>p</i> = 0.02) and RLI method (adjusted HR 0.56, 95% CI 0.43–0.75, <i>p</i> < 0.001). More systolic BP TTR is associated with a lower risk of MACE among individuals in PRECISION.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"27 7","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.70009","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.70009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Blood pressure (BP) is a dynamic vital sign with variability. Novel metrics that account for BP variability and longitudinal control are gaining interest, such as time in target range (TTR) assessments. TTR is the percentage of time a patient's BP is within a desired range. We sought to determine if systolic BP TTR was associated with major adverse cardiovascular events (MACE) among participants in the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen) trial. PRECISION was a 24 081-participant cardiovascular (CV) outcomes trial comparing celecoxib, naproxen, or ibuprofen in participants with increased CV risk. Systolic BP was in the target range if it was between 110 and 130 mm Hg. TTR was determined via traditional and Rosendaal linear interpolation (RLI) methods. Participants were categorized based on TTR achieved, <25%, 25%–<50%, 50%–<75%, or ≥75%. Hazard ratios (HR) and Kaplan–Meier survival curves were generated. Twenty thousand four hundred and eighty-seven participants had at least four BP readings available for analysis and a median follow-up of 27.6 ± 5.4 months. The cohort had a mean baseline BP of 125.2 mm Hg and a mean systolic BP of 127.5 mm Hg when accounting for all follow-up visits. A lower risk of MACE was observed among individuals with ≥75% TTR compared with those <25% using the traditional (adjusted HR 0.70, 95% CI 0.52–0.95, p = 0.02) and RLI method (adjusted HR 0.56, 95% CI 0.43–0.75, p < 0.001). More systolic BP TTR is associated with a lower risk of MACE among individuals in PRECISION.
血压(BP)是一个具有可变性的动态生命体征。考虑BP变异性和纵向控制的新指标正在引起人们的兴趣,例如目标范围内时间(TTR)评估。TTR是指患者血压在理想范围内的时间百分比。我们试图确定收缩压TTR是否与PRECISION(塞来昔布综合安全性与布洛芬或萘普生的前瞻性随机评价)试验参与者的主要不良心血管事件(MACE)相关。PRECISION是一项24081名参与者的心血管(CV)结局试验,比较塞来昔布、萘普生或布洛芬对CV风险增加的参与者的影响。收缩压在110 ~ 130 mm Hg之间即在目标范围内。TTR采用传统方法和Rosendaal线性插值(RLI)方法测定。根据TTR达到程度、25%、25% - 50%、50% - 75%或≥75%对参与者进行分类。生成风险比(HR)和Kaplan-Meier生存曲线。24487名参与者至少有4个血压读数可供分析,中位随访时间为27.6±5.4个月。考虑到所有随访,该队列的平均基线血压为125.2 mm Hg,平均收缩压为127.5 mm Hg。使用传统方法(校正HR 0.70, 95% CI 0.52-0.95, p = 0.02)和RLI方法(校正HR 0.56, 95% CI 0.43-0.75, p <;0.001)。在PRECISION患者中,更大的收缩压TTR与更低的MACE风险相关。
期刊介绍:
The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.